関連ニュース

IDEXX Laboratories NASDAQ: IDXX executives highlighted the company's diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Con

IDEXX Laboratories NASDAQ: IDXX executives reiterated the company's long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product inn

IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript

IDEXX Laboratories NASDAQ: IDXX outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investm

IDEXX Laboratories remains a buy, supported by a durable moat, strong recurring revenue, and a long-term international growth runway. Recent Q2 2026 results showed 9% organic revenue growth, EPS guida